ANI Pharmaceuticals Reports First Quarter 2019 Results and Reaffirms Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
ANI Pharma (ANIP) Tops Q1 EPS by 25c, Revenues Beat; Reaffirms FY19 Revenue Outlook
May 9, 2019 8:33 AM EDTANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $1.30, $0.25 better than the analyst estimate of $1.05. Revenue for the quarter came in at $52.9 million versus the consensus estimate of $50.57 million.
Net revenues of $52.9 million, an increase of 14% versus 2018GAAP net income of $0.4 million and diluted GAAP earnings per share of... More